H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Hookipa Pharma (HOOK) today and set a price target of $16.00. The company’s shares closed last Friday at $13.71.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 38.6% and a 53.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hookipa Pharma with a $21.50 average price target, which is a 54.0% upside from current levels. In a report issued on April 8, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $19.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.52 and a one-year low of $7.07. Currently, Hookipa Pharma has an average volume of 184.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body’s immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
